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Abstract
Triphenyl phosphate (TPhP) is a flame retardant additive frequently found in consumer products 
and household dust. We administered 170 μg of TPhP in maternal food from gestational day 8.5 to 
weaning and evaluated metabolic phenotypes of 3.5 month old male and female rats, and weight-
matched males up to 6 months, to assess the development of obesity and type 2 diabetes mellitus 
(T2DM), respectively. Perinatal TPhP exposure increased body and fat mass in 3.5 month old male 
and female rats, while leptin and cumulative energy intake were elevated in males and females, 
respectively. Independent of body mass, perinatal TPhP exposure accelerated T2DM onset in 
males and increased plasma non-esterified- fasting fatty acids. These observations suggest that 
perinatal exposure to TPhP exacerbates the development of obesity in male and female UCDavis-
T2DM rats and accelerates T2DM onset in male UCD-T2DM rats.
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1. Introduction
Type 2 Diabetes Mellitus (T2DM) is a serious metabolic disease presently affecting at least 
29.1 million people in the United States [1]. In 2012, the direct annual cost attributable to 
T2DM was more than $176 billion, while its indirect costs exceeded $69 billion [1]. T2DM 
is associated with many serious complications, including cardiovascular disease, blindness, 
end stage renal failure, and lower-limb amputations [1]. Worldwide, the incidence of T2DM 
is rising, with most of the increase occurring during the last 20 years [2,3]. Over the past 40 
years the prevalence of obesity has increased globally and now more people are obese than 
are underweight [4]. Interestingly, people today who eat and exercise the same amount as 
people 20 years ago are still more obese than their counterparts were two decades ago, 
though the composition of their diet and their other environmental exposures may differ [5]. 
This provocative finding is consistent with the hypothesis that exposure to environmental 
pollutants may contribute to the rapid increase in the prevalence of obesity and T2DM that is 
not explained by dietary factors and reduced physical activity [6–8].
Numerous candidate obesogens are lipophilic pollutants, suggesting adipose tissue is either a 
target of toxicity or a depot where toxicants are sequestered and from which they are 
released [9]. Obesogenic chemicals are added to consumer products [10,11] and are 
dispersed into the human environment where they become ubiquitous [11,12]. Some of these 
chemicals eventually distribute into human lipids, such as fat and breast milk [13], raising 
the possibility that they could act as developmental obesogens. Indeed, exposure to the high 
production volume lipophilic flame retardant mixture, Firemaster 550 (FM 550), from mid 
gestation to weaning resulted in increased body mass, increased circulating fasting glucose, 
and impaired glucose tolerance in Wistar rats (Patisaul 2013). Further, exposure to an 
individual component of the FM 550 technical mixture [12,14], triphenyl phosphate (TPhP), 
leads to lipid accumulation in mouse bone marrow stromal BMS2 cells at concentrations 
between 10–40 μM [15].
In addition to the metabolic toxicity associated with TPhP exposure alone or as a substantial 
component of FM 550 [15–17], TPhP has been found in human breast milk samples from 
Japan, the Philippines, and Vietnam [13]. Given these prior observations, we hypothesize 
that developmental exposure to the commercial flame retardant TPhP will produce effects 
consistent with endocrine disruption, exacerbate the development of obesity and increase the 
rate of T2DM onset in the UCD-T2DM rat, which is a well characterized animal model of 
T2DM [18].
2. Materials and Methods
2.1 Rat Husbandry and Diabetes Surveillance
We used the UCD-T2DM rat model of T2DM since this rat model more closely represents 
the pathophysiology and progression of T2DM in humans than other available rodent 
models of the disease [18]. UCD-T2DM rats develop progressive hyperglycemia along with 
hyperinsulinemia resulting from insulin resistance at T2DM onset accompanied by β-cell 
dysfunction and decompensation [18]. Because the incidence of T2DM among male and 
female rats is 92% and 43%, respectively, with an average age of onset of diabetes of 6 
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months in males and 9.5 months in females [18], we only used male rats for the diabetes 
study (Figure 1). This model has been validated and characterized for the investigation of the 
pathophysiology of T2DM, as well as T2DM prevention and treatment in numerous peer-
reviewed publications [18,20–22]
Animal care and maintenance was conducted in accordance with the applicable portions of 
the Animal Welfare Act and the U.S. Department of Health and Human Services’ Guide for 
the Care and Use of Laboratory Animals and approved by the University of California, 
Davis Institutional Animal Care and Use Committee. Study rats were kept in a climate 
controlled room at 25°C and 45% 60% average relative humidity on a 12 hour reversed light 
cycle. All rats were fed Harlan diet 2018 (3.1 kcal/g, 0.57 kcal fat, 1.8 kcal carbohydrates, 
0.74 kcal protein; Teklad Diets, Madison WI).
Adult non-pregnant female UCD-T2DM rats (n=16; 3 months old) were paired with males 
(n=10; 3–4 months old) for a 24 hour period at which point males were removed. This was 
defined as gestational day zero (G0) if a sperm plug was observed or if the female rats 
gained at least 30g over the next 7 days. The day of birth was designated postnatal day zero 
(P0). Pregnant dams were randomly assigned to an exposure group (n=8 per group), and 
received daily oral TPhP or ethanol vehicle exposure from G8 through weaning (P21) as 
described in section 2.2 below. Gestational length, litter size were recorded on P0 and the 
sex of pups was determined and recorded on P4. Body weights of all pups in each litter were 
obtained periodically from P4–21.
On P4 the litters were culled to 8 pups ensuring up to 4 males and 2 females in each litter by 
random selection (Figure 1A & 1B). This was done to ensure consistent exposure of pups 
between litters [13,23]. The time it takes to develop T2DM is accelerated among UCD-
T2DM rats with higher body weights on P21. Hence at weaning the largest pups were 
housed in same sex littermate groups of two females and up to four males as available 
(Figure 1A & 1B). Urine was collected from the dams using an adapted plastic wrap method 
outlined by Kurien [24]. Dams were placed in clean cages without bedding for at least 20 
minutes then using a pipette up to 500 μl of urine was collected in ethanol rinsed glass vials 
and placed on ice. At weaning all dams and remaining weanlings were sacrificed (90–330 
min post-exposure) by CO2 asphyxiation and rapid decapitation.
Two male rats weighing between 350g–400g on P61, from the TPhP group and the vehicle 
group were weight- matched across treatments for the diabetes study to eliminate 
confounding effects of body mass on the association between TPhP and T2DM onset 
(Figure 1B). This weight range was selected because male UCD-T2DM rats that are 
between 350–400g at 8 weeks of age develop T2DM at approximately 23 weeks of age [18]. 
Weight- matched rats were followed until 26 weeks or until they developed T2DM, which 
was defined as two consecutive weekly non-fasting glucose measurements of ≥200mg/dL 
[18] in accordance with the American Diabetes Association (ADA) guideline of diagnosing 
diabetes with a random plasma glucose of 200 mg/dL or higher [19]. The remaining rats 
were not weight-matched and followed for the 3.5 month obesity study (Figure 1A).
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The terminal procedures for rats in both the obesity and diabetes studies were identical. Prior 
to sacrifice, rats were fasted between 8–12 hours, their body weights recorded, and blood 
was collected from the tail as above prior to euthanasia. Rats were anesthetized with sodium 
pentobarbital and euthanized with a 1mL/kg intracardiac injection of saturated potassium 
chloride. Once cardiac movement had stopped for 30 seconds the rat was decapitated and the 
hypothalamus, liver, pancreas, heart, mesenteric adipose tissue, quadriceps, kidney, gonadal 
adipose tissue, inguinal adipose tissue, and brown adipose tissue were collected. All tissues 
were removed in the order listed above, wet weighed, and snap frozen in liquid nitrogen.
2.2 Exposure
Given that FM550 contains 17% TPhP [16], our oral TPhP dose of 170 μg per day is 
equivalent to the amount of TPhP present in the 1 mg FM 550 /rat /day dosed over the same 
developmental period that produced metabolic disruption in a previous study [17]. On 
average an adult ingests 28 mg of dust per day [25] making oral TPhP administration highly 
relevant to humans [12,25]. At 28 mg of dust per day, over the course of pregnancy and 
breastfeeding a woman would ingest a total of 17.5 g of dust [26]. Therefore it would require 
only 90 μg of TPhP per gram of dust for a woman to receive 21 mg/kg of TPhP. This is the 
same total exposure as rats in this study and well below 1800 μg of TPhP/g of dust, which to 
the best of our knowledge is the maximum observed level reported from samples collected in 
2007 and 2012 [12,27,28]. Triphenylphosphte (100% purity; Accustandard, New Haven, 
CT) was weighed to the nearest tenth of a mg, diluted into 100% ethanol (Fisher Scientific, 
Pittsburg, PA), and vortex mixed to yield a dose solution of 8.5 mg/mL.
Due to their taste aversion to the treat used as a dose vehicle by Patisaul [17], we instead 
dispensed 20 μL of ethanol with or without TPhP onto a ¼ mini Nilla wafer cookie vehicle 
(1 quarter equivalent to 1.75 kcal total, 0.65 kcal fat, 1.05 kcal carbohydrates, 0.05 kcal 
protein; Nabisco, East Hanover, NJ[29] and allowed the ethanol to completely evaporate 
before administration to UCD-T2DM rats (Figure 1A & 1B). Dams were habituated to 
eating the ¼ mini Nilla wafer prior to exposure from G4-7 (Figure 1A & 1B), and all rats 
readily consumed the ¼ mini Nilla wafer within 5 min for all groups by the onset of the 
exposure period.
2.3 Urine Analysis for the analysis of Diphenylphosphate (DPhP)
Urine analysis for the main and non-volatile metabolite of TPhP, diphenylphosphate (DPhP), 
was performed with small modifications of a method as previously described [30]. Briefly, 
DPhP was measured using mixed – mode anion exchange solid phase extraction and a 
labeled internal standard (deuterated (d10)-DPhP). The modifications included that only 500 
μL samples were used for each analysis rather than 1 mL and the samples had to be diluted 
200 times with the elution solvent, after the clean-up preparation, due to high levels of DPhP 
detected (values exceded the upper limits of the quantitation curve). The analysis was 
performed on a liquid chromatographic system (LC) coupled with tandem mass 
spectrometry (MS/MS) applying negative electrospray ionization (N-ESI). Recoveries for 
both DPhP and the labeled analog were 105% ±13% and 122% ± 25%, respectively. For 
quality assurance purposes, DPhP was evaluated in laboratory blanks and six levels of 
quality control samples (QCs) during each analysis. DPhP levels in laboratory blanks and 
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materials averaged to 0.3 ng/mL. The method detection limit was calculated by serial 
dilutions of the lowest calibration standard (0.1 ng/mL) and spiked into 1 mL of pool urine 
samples that were processed with the whole clean up protocol. The method detection limit 
(MDL) was set as the lowest amount of analyte that provided a response with: a) at least 5 
times the response of the matrix sample; b) both precision (relative standard deviation, RSD) 
and accuracy (error, %Er) ≤20%. Limit of detection (LOD) was the lowest value detected 
with RSD >3 So, where So was the standard deviation of the signal received from a urine 
sample processed and analyzed three times with the same chromatographic method and 
detected with %Er ≤20%. Those two values for DPhP were 0.2 and 0.1 ng/mL respectively.
2.4 Metabolic and Physical Parameters
Metabolic parameters were evaluated across the lifespan as detailed here and in Figure 1A 
and 1B. Body weight and food intake per cage were recorded weekly in rats from the obesity 
and diabetes studies, from P21. Every 2 weeks body temperature was assessed in rats from 
the obesity and diabetes studies by inserting a thermocouple probe into the rectum (BAT-10, 
Physitemp, Clifton, NJ). Cumulative energy intake (kcal) was calculated as the difference in 
food weight divided by the number of rats that had access to it and the number of days they 
had access, and transformed to kcal [31].
2.4.1 Glucose—Non-fasting blood glucose (AlphaTrak; Abbott Laboratories, Abbott Park, 
IL) was recorded weekly beginning in P21 aged rats from the obesity and diabetes studies. 
Tail blood was collected from all rats at 3 months of age fasted for between 8–12 hours to 
determine fasting blood glucose (AlphaTrak).
At 13 weeks of age, 1 rat/sex/litter/treatment group in both the obesity and diabetes study 
were randomly assigned to receive an intraperitoneal glucose tolerance test (ipGTT) (Figure 
1A & 1B). The rats receiving the ipGTT were administered 1.0 g D-glucose/kg body weight 
after an overnight 14 hour fast, and blood was collected from the tip of the tail to determine 
fasting blood glucose [32] at 0, 15, 30, 45, 60, 90, and 120 minutes after the D-glucose 
bolus. We determined total area under the curve (AUC) using the trapezoidal approach.
At sacrifice, blood was collected from the tail of rats in the obesity and diabetes studies, 
after fasting for 8–12 hours (Figure 1A & 1B) to determine fasting blood glucose. Fasted 
plasma collected at sacrifice in the diabetes study (Figure 1B) was tested for glycated 
albumin (Diazyme; Powey, CA), a glycemic indicator.
2.4.2 Hormones—At 13 weeks of age 1 rat/sex/litter/treatment group in both the obesity 
and diabetes studies were randomly assigned to receive an intraperitoneal insulin tolerance 
tests (ipITT) (Figure 1A & 1B). The rats receiving the ipITT were fasted for 4 hours and 
then 1.0 U Humulin R/kg body weight was administered i.p. and blood was collected from a 
tail cut to determine fasting blood glucose at 0, 15, 30, 45, 60, 90, and 120 minutes after the 
Humulin R bolus.
At sacrifice, tail blood was collected from obesity and diabetes studies- rats (Figure 1A & 
1B) fasted between 8–12 hours and thyroid stimulating hormone (TSH) (Alpco Diagnostics; 
Boston, MA), T4 (CalBiotech; Spring Valley, CA) leptin (Meso Scale Discovery; 
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Gaithersburg, MD), and adiponectin (Meso Scale Discovery) were evaluated with blinding 
to treatment. Tail blood was collected from all rats at 3 months of age (Figure 1A & 1B) and 
from diabetes study (Figure 1B) rats at the time of sacrifice after fasting for between 8–12 
hours to determine plasma insulin by ELISA (Mercodia; Uppsala, Sweden) while blinded to 
treatment. HOMA-IR, an indicator of insulin resistance, and HOMA-%B, an indicator of 
pancreatic beta cell function, were calculated using the HOMA2 Calculator, available at 
https://www.dtu.ox.ac.uk, using fasting blood glucose and specific fasting plasma insulin 
[33].
2.4.3 Lipids—All lipid measures described in this section were performed by investigators 
blinded to treatment. Tail blood was collected from rats in the obesity and diabetes studies at 
13 weeks of age and at sacrifice, respectively, after fasting for between 8–12 hours (Figure 
1A & 1B) to determine total cholesterol, total non-esterified fatty acids (NEFA), and plasma 
triglycerides by enzyme based colorimetry (Wako Chemicals; Richmond, VA).
Non-esterified Fatty Acid Profiling: Non-esterified fatty acids (NEFAs) were further isolated 
from fasted plasma, and collected from diabetes study rats, as previously described by 
Smedes [34] and Gladine [35]. Specifically, plasma aliquots (50 μL) were enriched with a 
suite of extraction surrogates, including isotopically labeled triglycerides and phospholipids, 
along with rare cholesteroyl esters and fatty acids as previously reported (Grapov, Adams, 
Pedersen, Garvey, & Newman, 2012). Lipids were then extracted twice with 10:8:11 
cylcohexane/2-propanol/1M ammonium acetate (v/v/v), and the organic extract was dried 
and reconstituted in 2:1 methanol/toluene (v/v), including pentadeca-(10Z)-enoic acid (Nu-
Check Prep Inc.) to track methylation efficiency. Fatty acids were derivatized with 2M 
(trimethylsilyl) diazomethane (Sigma-Aldrich, St. Louis, MO) in hexanes, reduced to 
dryness and reconstituted in hexane containing methyl tricosanoate (Nu-Chek Prep)and 
analyzed by GC-MS on an Agilent 6890/5973N MSD (Agilent Technologies, San Jose, CA) 
with electron impact ionization using a 30m x 0.25mm x 0.25μm DB-225ms to separate 
analytes. Quantification was accomplished with ChemStation vE.02.14 (Agilent 
Technologies, Santa Clara, CA) using internal standard methodologies.
Lipid Mediator Profiling: Non-esterified oxylipins, endocannabinoids, endocannabinoid-like 
monoacylglycerols and N-acylethanolamines, and nitrated fatty acids were quantified by 
tandem quadrupole mass spectrometry using slight modifications of previously reported 
methods [36]. Briefly, analytes were isolated from hypothalami collected from female 
obesity study rats, as previously described [37] but without ester hydrolysis. Hypothalamus 
aliquots (~20–25 mg) aliquots were enriched with isotopically labeled surrogates and 
extracted with 1:10:5 methanol/ethyl acetate/deionized water (v/v/v). Extracts were dried 
under vacuum, reconstituted in 1:1 MeOH/acetonitrile (v/v) containing internal standards, 
and filtered at 0.1μm through a PVDF membrane. Analytes were separated on a 2.1 x 150 
mm, 1.7μm Acquity UPLC BEH column and detected by negative mode (oxylipins and 
nitrated fatty acids) and positive mode (endocannabinoids and endocannabinoid-like 
compounds) electrospray ionization using multiple reaction monitoring on an API 4000 
QTrap (Sciex, Framingham, MA, USA). Analytes were quantified against calibration curves 
and correcting for surrogate losses using Sciex MultiQuant version 3.0.2.
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2.5 Semi-quantitative PCR
The RNeasy kit (Qiagen; Hilden, Germany) was used to extract mRNA from aliquots of 
pulverized mesenteric fat to be used in reverse transcription PCR (Applied Biosystems; 
Foster City, CA) and semi-quantitative PCR while blinded to treatment. RNA was 
quantitated by absorbance at 260 nm wavelength and retained with a purity threshold > 1.8 
for the 260/280 ratio (NanoQuant, Tecan; Männedorf, Switzerland). Semi-quantitative PCR 
was performed using SYBR Green primers: Peroxisome proliferator activated receptor 
gamma (Pparg, F: TGTGAAGGATGCAAGGGTTT, R:CATTCGCCCAAACCTGATGG), 
CCAAT/enhancer binding protein (C/EBP) alpha (Cebpa, 
F:TGCGCAAGAGCCGAGATAAA, R:GCGGTCATTGTCACTGGTCA), CCAAT/
enhancer binding protein (C/EBP) beta (Cebpb, F:CAAGATGCGCAACCTGGAGA, 
R:AGCTGCTTGAACAAGTTCCG) in mesenteric fat using beta actin (Actb, 
F:CTGACAGGATGCAGAAGGAG, R:GATAGAGCCACCAATCCACA) as an endogenous 
control; the endogenous control did not vary significantly across treatment groups. All 
primers were designed for Rattus norvegicus by querying the Pubmed gene library with the 
NCBI Primer-BLAST tool [38]. Primers were designed to span an exon-exon junction with 
each pair separated by at least one intron in the corresponding genomic DNA. The 2−ddCT 
method was used to approximate relative transcript fold change between treatment groups 
[39].
2.6 Statistical Analyses
Relative tissue weights were determined by dividing each tissue weight by body weight. 
Metabolic parameters were statistically analyzed as follows to determine means ± standard 
error of the mean (SEM) at a significance threshold of P < 0.05. Analyses of non-fasting 
blood glucose, HOMA-IR, HOMA-%B, body weight, temperature, tissue weights, relative 
tissue weights, TSH, adiponectin, insulin, triglycerides, cholesterol, total NEFA, and RNA 
expression were assessed by modeling the fixed effect of perinatal TPhP and the random 
effect of litter while stratifying by sex and study group shown in figures 1A and 1B using 
fixed effects for treatment and litter as a repeated event (PROC MIXED, SAS). All mixed 
models used LSMEANS to find the mean and SEM and PDIFF to test significance. We also 
tested for sex interactions at threshold p < 0.1 and if it was significant it was included in the 
model statement in addition to the sex-stratified models described above. The distribution of 
the data was checked for normality before T-tests were used to evaluate gestation length, 
litter size, sex ratio, dam body weight, luciferase E2, cumulative energy intake, and targeted 
lipids because only one rat per litter was included (PROC TTEST, SAS). ITTs and GTTs 
were evaluated by stratifying by sex and study group (Fig 1) without random effects because 
only one rat per litter was included (PROC GLM, SAS). We evaluated whether perinatal 
TPhP accelerated the onset T2DM by using survival analysis with treatment as a fixed effect 
and litter as a repeated event (PROC LIFETEST, SAS). This the best method of analyzing 
differences in the onset of T2DM because survival analysis accounts for the non-normal 
distribution of time to event data and can account for censoring, that is, ending the 
observation period before all rats have developed T2DM.
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3. Results
3.1 Perinatal TPhP is not overtly toxic
We examined the dams and pups through weaning to determine if any gross maternal or 
developmental TPhP toxicity was present at this dose. No significant differences were 
observed in the length of gestation, litter size, sex ratio, or the body weight of the dams or 
pups at weaning (Table 1), suggesting that exposure to TPhP was not overtly toxic with 
respect to these parameters.
3.2 Perinatal exposure to TPhP increases energy intake and body weight
Food intake and body weight were measured weekly in rat offspring and the cumulative 
energy intake was calculated per rat (Figure 2B & 2D). In both female and male rats, those 
with perinatal TPhP exposure had significantly higher body weights compared with the 
vehicle-treated control rats starting at week 9 and week 13, respectively (p < 0.05; Figure 2A 
& 2C). This effect of TPhP became more marked as the animals aged (treatment x age 
interaction pinteraction < 0.05, and < 0.01 for females and males, respectively). We also 
observed that the cumulative energy intake was higher in the female rats exposed to TPhP 
(7.8%, p < 0.05, Figure 2B) but not in the male rats (Figure 2D).
Because core body temperature contributes 60–90% to total energy expenditure [40], we 
measured core body temperature to evaluate whether perinatal TPhP exposure also modified 
energy expenditure. Temperature measurements taken biweekly were not significantly 
different across treatments in the obesity study (Supplemental Figure 1). These data show 
that both male and female rats perinatally exposed to TPhP had significantly elevated body 
weight that was at least partially explained by increased caloric intake in female rats.
3.3 Perinatal TPhP exposure increases adult rat fat pad weights
Given that body weight is a non-specific assessment of adiposity, tissues were collected to 
assess changes in the weight of adipose depots, as well as evidence of overt toxicity, 
associated with perinatal TPhP exposure. No differences in the weights of tissues collected 
were observed across treatment groups in female pups sacrificed at weaning (Supplemental 
Table 1). No difference was seen between vehicle and treatment in both the absolute and 
relative weights of livers, quadriceps muscle, heart, or pancreas collected at sacrifice in both 
male and female adult rats in the obesity study (Supplemental Figure 2A and 2B). The 
kidney weight relative to total body weight was significantly decreased (p < 0.05) in the 
treated adult male rats in the obesity study however the absolute weight was not significantly 
different between treatments (Supplemental Figure 2A and 2B). Overall these results suggest 
there was no overt toxicity to non- adipose tissues of rats exposed to TPhP.
Significant changes were observed in the mean weight of fat depots collected from both 
male and female adult rats in the obesity study (Figure 3A). In the adult female rats, the 
mean absolute weights of mesenteric fat and brown adipose depots were significantly 
increased in the TPhP- exposed group vs. vehicle control (p < 0.05, Supplemental Figure 
2A) but after adjusting for body weight only the mesenteric fat remained larger (17%) in the 
female rats with perinatal TPhP exposure (p < 0.05, Figure 3A). In the adult male rats, the 
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absolute inguinal fat, gonadal fat and mesenteric fat weights were significantly increased in 
the TPhP exposed group vs. vehicle controls (p < 0.05, Supplemental Figure 2A) and these 
fat depots remained significantly larger (29%, 17%, and 26% respectively) after adjusting 
for total body weight (p < 0.05, Figure 3A). Further, independent of sex, both the relative 
inguinal and mesenteric fat pads were significantly increased in the rats prenatally exposed 
to TPhP compared with vehicle-treated control animals (p < 0.05, Figure 3A). These results 
demonstrate that perinatal TPhP exposure increased body adiposity and the size of multiple 
fat pads in both male and female rats particularly in high risk sites such as inguinal and 
mesenteric fat pads. Further the data show that males accumulate more fat in these areas 
than females.
3.4 Perinatal TPhP exposure does not alter glucose, insulin, or lipids in early adulthood
Because we have reported that body weight is a determinant of the timing of T2DM onset in 
this rat model [18], we suspected that increased adiposity of 3 month old rats perinatally 
exposed to TPhP could lead to abnormalities in glucose and lipid homeostasis. However, 
fasting lipids (Supplemental Figure 4) and glucose (Figure 4) were not different between 
treatments in either male or female rats. Further, glucose responses during insulin and 
glucose tolerance tests were not significantly different between treatments in either male or 
female rats (Figure 4). No difference was observed in areas under the curve for the glucose 
tolerance test (Figure 4A & 4B inset). These data suggest that despite increased adiposity in 
animals exposed to perinatal TPhP, glucose, insulin, and lipids were not altered in early 
adulthood.
3.5 Perinatal TPhP does not alter thyroid hormones
Previous studies have reported that FM 550 is capable of increasing total T4 in rat dams 
[17]. Therefore we examined whether perinatal TPhP disrupts the thyroid hormone axis of 
rats in the obesity study. We found that total T4 tended to be lower in the male rats 
perinatally exposed to TPhP (p = 0.08, Figure 5) and no significant differences were 
observed in TSH for the male and female rats perinatally exposed to TPhP (Figure 5). These 
data suggest that increased adiposity by perinatal TPhP exposure is not mediated through 
disruption of the thyroid hormone axis of adult offspring.
3.6 Perinatal TPhP exposure increases fasting leptin
Because plasma leptin levels are positively related to adiposity in both rats and humans [41–
44], we suspected that perinatal TPhP exposure would be associated with increased fasting 
leptin in rats of the obesity study. Consistent with this suspicion, there was a doubling of 
plasma leptin in male rats exposed to TPhP compared with vehicle-treated control male rats 
while in female rats there was only a 50% increase of plasma leptin concentrations 
(pinteraction < 0.01). Furthermore, the leptin to adipose ratio, a surrogate for leptin resistance, 
was 32% higher in the TPhP exposed vs. vehicle control females in the obesity study (p < 
0.05). While the leptin to adipose ratio for TPhP exposed vs. vehicle control males in the 
obesity study, was 39% higher it was not significantly different, consistent with leptin 
resistance [45,46]. Indeed, independent of sex and body weight there was a significant 
increase of fasting plasma leptin concentrations (p < 0.01) between the vehicle and TPhP 
exposed rats in the obesity study (Figure 5). However, adiponectin, a hormone linked to 
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visceral adiposity [45], was not altered by TPhP exposure (Figure 5). These measurements 
of adipose tissue hormones suggest that the effects of increased adiposity resulting from 
perinatal TPhP exposure is specific for leptin, and do not appear to influence adiponectin.
3.7 Hypothalamic lipid mediators are unchanged by perinatal TPhP exposure
Lipid mediators, including oxylipins, nitrated fatty acids, endocannabinoids, and 
endocannabinoid-like compounds, were analyzed among rats of the obesity group as they 
have been shown to play important roles in inflammatory signaling and energy balance 
[47,48]. No difference in the concentrations of endocannabinoids, endocannabinoid-like 
compounds (Supplemental Table 2), oxylipins, or nitrated fatty acids (Supplemental Table 3) 
was detected in the hypothalamus of female rats in the obesity study. These data suggest that 
the increase in adiposity seen in female rats in the obesity study is likely not driven by 
changes in the hypothalamic tone of the lipid mediators measured [49].
3.8 mRNA expression markers of adipogenesis
To assess whether the observed increased fat mass of rats perinatally exposed to TPhP was 
the result of adipocyte proliferation, we measured changes in the expression of three master 
regulators of adipogenesis [50]. However, we found no significant differences in the RNA 
expression of Pparg, Cebpa, or Cebpb across treatment groups in both male and female adult 
rats in the obesity study (Figure 3B). There was an apparent interaction between treatment 
and sex for Pparg (pinteraction < 0.1), where among rats with perinatal TPhP exposure, the 
males have greater Pparg expression than observed in females (p < 0.05), yet this sex 
difference was absent in the vehicle exposed rats (Figure 3B). There was also an interaction 
between treatment and sex for Cebpa transcript abundance (pinteraction < 0.1); yet this was 
driven by a non-significant trend of higher Cebpa in males compared to females among 
those exposed to TPhP during development (Figure 3B). These data suggest that the increase 
in adiposity of male rats might be driven by a Pparg mediated increase in adipogenesis.
3.9 Perinatal TPhP accelerates onset of T2DM in weight- matched male rats
To examine whether perinatal TPhP exposure accelerates the onset of T2DM, T2DM was 
diagnosed from two consecutive weekly non-fasting glucose measurements of ≥200mg/dL, 
according to ADA diagnostic guidelines [19]. We found that perinatal exposure to TPhP 
accelerated the onset of T2DM in weight-matched male rats (p < 0.05 PROC LIFETEST, 
Figure 6). Indeed, from the first T2DM case observed to the end of the study, male rats with 
perinatal TPhP exposure had a higher prevalence of T2DM than control rats independent of 
body mass. For example, by 26 weeks when the study was censored, 79% of male rats 
perinatally exposed to TPhP developed T2DM while only 33% of the vehicle treated rats 
developed T2DM. Consistent with the first case of T2DM of the study being observed in 116 
day old rats with perinatal TPhP exposure, no difference in GTT or ITT was observed in the 
3 month old weight matched males (Supplemental Figure 5). Because of the much longer 
latency of T2DM onset in female UCD-T2DM rats, we made an a priori decision to exclude 
female rats from the diabetes study (Figure 1B) [18], and unfortunately cannot extend our 
observation of early T2DM onset to female rats here.
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3.10 No effect of perinatal TPhP exposure on adiposity or energy balance in weight-
matched male rats
Although male rats were weight-matched between exposure groups for the diabetes study 
when they were 2 months of age (Figure 1B), because of our earlier observations of 
adiposity resulting from hyperphagia, we considered whether increased adiposity could 
explain the earlier onset of T2DM in rats perinatally exposed to TPhP. However, no 
differences were observed for body weight, cumulative food intake, biweekly body 
temperature, weights of all tissues collected, or the majority of average daily food intake 
measurements (Figure 7, Supplemental Figure 1). These results suggest that accelerated 
onset of T2DM in rats following perinatal exposure to TPhP was independent of adiposity 
and energy balance.
3.11 Non-esterified Fatty Acids are increased by Perinatal TPhP exposure in weight-
matched male rats
We conducted preliminary analyses to further characterize the metabolic profile of these rats 
at the end of the diabetes study. Despite the increased prevalence of diabetes in the TPhP 
exposed group, fasting blood glucose was significantly higher in the control group compared 
to the TPhP exposed group (Figure 8A, p < 0.05). While fasting glycated albumin was not 
significantly altered by treatment, its trend was consistent with the fasting blood glucose (p 
< 0.1, Figure 8A). No significant treatment differences were observed between TPhP and 
vehicle exposed rats in the diabetes study for fasting insulin, TSH, total T4, leptin, 
adiponectin, triglycerides, or cholesterol (Figure 8B–C).
Given these seeming paradoxical fasting metabolic parameters among rats with elevated 
prevalence of T2DM, we evaluated HOMA-IR and HOMA-%B to determine if the 
relationship between fasting glucose and insulin revealed insulin resistance and beta cell 
dysfunction, respectively. We found that perinatal exposure to TPhP had no impact on 
HOMA-%B, indicating beta cells had not yet become impaired at this early stage of T2DM 
(Figure 8D). However, perinatal TPhP exposure elevated HOMA-IR, consistent with insulin 
resistance (Figure 8D).
Further consistent with insulin resistance, we found that total NEFA was significantly 
increased among fasting rats perinatally exposed to TPhP compared to their weight-matched 
controls in the diabetes study (Figure 8B). To further evaluate changes in total NEFA, we 
quantified individual fatty acids in weight- matched male rats from the diabetes study. 
Perinatal TPhP exposure significantly increased plasma concentrations of a number of fatty 
acids including palmitic acid, cis-9-palmitoleic acid, oleic acid, and cis-vaccenic acid (p < 
0.05) while linoleic acid, gamma-linolenic acid, and alpha-linolenic acid along with the 
stearic acid-palmitic acid and oleic acid-stearic acid ratios were all approaching significance 
(p < 0.1, Table 2). Because of these results, total saturated fatty acids, total mono-
unsaturated fatty acids, and total NEFA were all significantly elevated in adult male rats 
following perinatal TPhP exposure (Table 2). These elevations in fatty acids after perinatal 
TPhP exposure are consistent with a diabetic phenotype and have been positively associated 
with insulin resistance and T2DM independent of body weight [51–53][36].
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4. Discussion
In this study, we report that TPhP exposure during gestation and lactation increased obesity 
phenotypes in male and female UCD-T2DM rats well before the onset of T2DM. 
Independent of body mass, this perinatal TPhP exposure accelerated the onset and increased 
the prevalence of T2DM in male UCD-T2DM rats. While mechanisms underlying this 
accelerated onset of T2DM are not yet understood, consistent with our findings here, the 
pathophysiology of T2DM has previously been shown to be driven by insulin resistance in 
this rat model of T2DM [18]. Changes in free fatty acids [54,55] are recognized to 
contribute to impairments of glucose homeostasis. In particular, palmitic acid, cis-9-
palmitoleic acid, oleic acid, and cis-vaccenic acid were increased by perinatal TPhP 
exposure in our diabetes study, and these fatty acids along with the stearic acid-palmitic acid 
have been positively linked to insulin resistance, leptin resistance, T2DM, inflammation, and 
heart disease [51–53,56–59]. This is the first evidence that low-level, developmental 
exposure to TPhP can increase the risk of developing insulin resistance and T2DM, and that 
this risk is linked to alterations of circulating fatty acids. Given TPhP is a major component 
of the second most common flame retardant applied by polyurethane foam [11,60], a 
common consumer good, our results may have significant public health implications. Future 
studies of perinatal TPhP exposure should characterize the molecular mechanisms of its 
pathophysiology during the development and progression of T2DM in both male and female 
rats with particular attention to elucidating the seeming paradox of lower fasting glucose in 
the TPhP-treated rats.
The increased body and fat mass in both male and female rats following perinatal exposure 
to TPhP in the obesity study suggests that TPhP is an environmental obesogen. This increase 
in body and fat mass appeared to be the result of an energy imbalance resulting from 
increased cumulative energy intake in the females, with a similar trend being observed in the 
males. This suggests that increased appetite is the most likely contributor to increased 
adiposity in female rats exposed to perinatal TPhP. Moreover, the increase in body weight is 
the result of increased fat deposition, particularly in mesenteric fat, a visceral depot which 
has been linked to insulin resistance and metabolic syndrome [61,62]. While we did not 
measure whole body energy expenditure by calorimetry, the majority of thermogenic energy 
expenditure [40], as assessed by biweekly body temperature measurements, was not 
significantly altered by perinatal TPhP exposure (Supplemental Figure 1).
A number of hormones and receptors have been implicated in the regulation of food intake 
and energy metabolism, including leptin [45]. In the obesity study, plasma leptin 
concentrations were elevated in both male and female rats exposed to TPhP. The greater 
increase of plasma leptin observed in male compared with female rats is most likely due to 
obesity- associated leptin resistance in male rats perinatally exposed to TPhP, as indicated by 
their elevated leptin to adipose ratio [42,63]. Further, along with males rats having higher 
basal leptin levels compared to females, the significant increase mass of all fat depots 
suggests a larger capacity for leptin production [43,63,64].
Our results indicated there was also an increase in the adipose expression of Pparg in 
mesenteric adipose tissue in male rats exposed to TPhP. This is consistent with in vitro 
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experiments that have reported that TPhP activates PPARG [65]. In agreement with the 
observed phenotypes, exposure to other PPARG agonists, tributyltin or Rosiglitazone, also 
increased adiposity in offspring [66]. However, we know of no studies evaluating the effects 
of prenatal PPARG agonists on the risk of developing type-2 diabetes in offspring. If 
perinatal PPARG agonism has residual anti-diabetic activity, as would be expected by known 
pharmacological effects of PPARG agonists, this may help explain the paradoxical modest 
reduction of fasting glucose observed in the diabetic rats perinatal exposed to TPhP in this 
study. Future studies will need to further evaluate this possibility.
5. Conclusions
This study has demonstrated that developmental exposure to the commercial flame retardant 
TPhP increases adiposity in both male and female UCD-T2DM rats, most likely due to an 
increase of energy intake. In addition, perinatal TPhP exposure accelerates the onset of 
T2DM and impairs fatty acid levels in male UCD-T2DM rats independent of body weight. 
We have also shown that the UCD-T2DM Rat model is a valuable model for testing the 
effects developmental exposure to environmental pollutants that can act as obesogens and 
disrupters of metabolic homeostasis and their consequences on the development of obesity 
and diabetes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Perinatal TPhP exposure increased body and fat mass in male and female rats.
• Perinatal TPhP exposure increased circulating leptin in male rats.
• Perinatal TPhP exposure increased cumulative energy intake in female rats.
• Independent of body mass, perinatal TPhP exposure accelerated T2DM onset 
in male rats.
• Perinatal TPhP exposure increased plasma non-esterified- fasting fatty acids, 
including total saturated and monounsaturated fatty acids, in male rats.
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Figure 1. Study groups
(A) Obesity study design for two female and up to two male rats per litter (L) per treatment 
which terminated when rats were sacrificed (Sac) at 3.5 months of age (n=6–8 L). (B) 
Diabetes study design for two weight-matched male rats per litter per treatment which 
terminated when rats were sacrificed at their onset of T2DM or at 6 months of age (n=8 L). 
Diabetes was diagnosed with two random plasma glucose measurements of ≥200 mg/dL per 
ADA guidelines [19]. Gestational Day (G), Postnatal Day (P), Insulin tolerance test (ITT), 
Glucose tolerance test (GTT)
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Figure 2. Weekly physical measurements of male and female UCD-T2DM rats, obesity study
(A) Female body weight from 3–15 weeks (n=8 TPhP and n=8 Veh exposed litters, 
treatment x age, pinteraction < 0.05). (B) Female cumulative energy intake (n=8 TPhP and n=8 
Veh exposed litters). (C) Male body weight from 3–15 weeks (n=6 TPhP- and n=7 Veh 
exposed litters, treatment x age pinteraction < 0.01). (D) Male cumulative energy intake (n=6 
TPhP and n=7 Veh exposed litters). Figure depicts means ± SEM. *p < 0.05, **p < 0.01
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Figure 3. Fat pads and qPCR quantification from male and female UCD-T2DM rats euthanized 
when 3.5 months old, obesity study
(A) Weights of individual fat deposits relative to body weight (B). qPCR quantification of 
master regulators of adipogenesis in mesenteric fat from adult rats.
Inguinal Fat (IF), Gonadal Fat (GF), Mesenteric Fat (MF), Brown Adipose Tissue (BAT). 
Figure depicts means ± SEM *p < 0.05
Green et al. Page 21
Reprod Toxicol. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Glucose and insulin tolerance tests performed at 3 months of age on male and female 
UCD-T2DM rats, obesity study
(A, C) Plasma glucose excursion in response to intraperitoneal glucose administration (1 
g/kg body weight and 75% D-glucose solution) in nondiabetic rats after an overnight fast. 
Inset shows area under the curve. (B, D) Plasma glucose excursions in response to 
intraperitoneal insulin administration (0.5 U/kg body weight and 1U/mL insulin solution) in 
nondiabetic rats after an overnight fast. Inset shows fasting insulin adjusted for body weight. 
Pinteraction<0.1 for treatment and sex tested on AUC. Figure depicts means ± SEM. (n=6–8L)
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Figure 5. Hormones at sacrifice in adult male and female UCD-T2DM rats, obesity study
The pinteraction=0.6, 0.006 and 0.21 for Thyroid stimulating hormone, Leptin, and 
Adiponectin, respectively. (n=8 L TPhP and n=8 L Veh in exposed females and n=6 L TPhP 
and n=8 L Veh in exposed males). Figure depicts means ± SEM. ** P < 0.01 *** p < 0.001
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Figure 6. Kaplan-Meier plot of T2DM incidence in weight- matched male UCD-T2DM rats, 
diabetes study
Weight-matched male rats were developmentally exposed to 170ug of TPhP/day from P4 
through GD21. P < 0.05 by log rank test with censoring at 26 weeks of age (LIFETEST).
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Figure 7. Physical measurements of weight-matched male UCD-T2DM rats, diabetes study
(A) Weekly body weight from 3–26 weeks (n=8 TPhP and n=8 Veh exposed litters). (B) 
Average daily food intake calculated from weekly measurements. Inset shows lifetime food 
consumption (n=8 L TPhP and n=8 L Veh exposed litters). (C) Absolute weights of all 
tissues collected at diabetes onset or the 6 month censor date. Figure depicts means ± SEM. 
*p < 0.05
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Figure 8. Fasting blood analysis of weight- matched male UCD-T2DM rats at sacrifice, diabetes 
study
(A) Glucose and glycated albumin. (B) Triglycerides, Cholesterol, and Non-Esterified Fatty 
Acids (NEFA), (C) Insulin, Thyroid Stimulating Hormone (TSH), Total T4, Leptin, and, 
Adiponectin and (D) HOMA-%B and HOMA-IR. Figure depicts means ± SEM. *p < 0.05
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Table 1
Gestation and Pre-weaning
Outcome Vehicle Control Treatment (TPhP)
Gestation Length (days) 22.9 ± 0.1 23.6 ± 0.5
Litter Size 13.6 ± 0.8 13.3 ± 0.8
Sexes per Litter (P4) ♂6.9 ± 0.7
♀6.1 ± 0.8
♂5.5 ± 1.0
♀6.5 ± 0.5
Pup BW at weaning (g) ♂57.2 ± 3.1
♀54.1 ± 3.5
♂57.0 ± 3.6
♀53.8 ± 4.6
Dam BW at weaning (g) 330.4 ± 7.9 334.0 ± 4.3
Dam TPhP metabolite (DPhP) in urine at weaning (ng/mL) 2.6 ± 0.6 2778.0 ± 2104.0
8 Dams per exposure group: gestation length, litter size, sex ratio, or Dam body weight at sacrifice.
3 Dams per exposure group : DPhP. Table depicts means ± SEM
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Table 2
Non-esterified fatty acid measured in plasma from male rats, diabetes study
Metabolite (μM) Vehicle Control Treatment (TPhP)
Saturated
Pentadecylic acid (15:0) 1.8 ± 0.1 1.9 ± 0.1
Palmitic acid (16:0) 190 ± 10 220 ± 10 *
Margaric acid (17:0) 1.33 ± 0.04 1.46 ± 0.07
Stearic acid (18:0) 38 ± 1 41 ± 2
Arachidic acid (20:0) 0.66 ± 0.04 0.65 ± 0.03
Mono-Unsaturated
trans-9-Palmitoleic acid (16:1n7t) 4.5 ± 0.3 4.8 ± 0.3
cis-9-Palmitoleic acid (16:1n7) 42 ± 4 57 ± 6 *
Oleic acid (18:1n9) 124 ± 6 146 ± 8 *
cis-Vaccenic acid (18:1n7) 22 ± 1 27 ± 1 **
Nonadecylic acid (19:1n7) 2.6 ± 0.4 2.6 ± 0.3
n6-PUFA
Linoleic acid (18:2n6) 188 ± 9 210 ± 9
Gamma-Linolenic acid (18:3n6) 2.1 ± 0.1 2.5 ± 0.1
Eicosadienoic acid (20:2n6) 3.4 ± 0.3 3.9 ± 0.2
Dishomo-gamma-linolenic acid (20:3n6) 4.9 ± 0.4 5.5 ± 0.5
Arachidonic acid (20:4n6) 67 ± 3 68 ± 3
Docosadienoic acid (22:2n6) 0.53 ± 0.08 0.48 ± 0.06
Adrenic Acid (22:4n6) 5.7 ± 0.2 8 ± 1
Osbond acid (22:5n6) 2.6 ± 0.2 3.4 ± 0.8
n3-PUFA
Alpha-linolenic acid (18:3n3) 16 ± 1 19 ± 1
Stearidonic acid (20:4n3) 0.58 ± 0.03 0.61 ± 0.04
Eicosapentaenoic acid (20:5n3) 1.67 ± 0.08 2.0 ± 0.2
Docosapentaenoic acid (22:5n3) 4.9 ± 0.3 5.9 ± 0.5
Docosahexaenoic acid (22:6n3) 42 ± 3 43 ± 3
Totals
Total Saturated Fatty Acids 230 ± 10 260 ± 20 *
Total Mono-Unsaturated Fatty Acids 190 ± 10 240 ± 10 *
Total n6-PUFA 270 ± 10 300 ± 10
Total n3-PUFA 65 ± 3 70 ± 4
Total NEFA 760 ± 30 870 ± 40 *
Table depicts means ± SEM.
*p < 0.05,
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**p < 0.01
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